PREOPERATIVE PLASMA TETRANECTIN AS A PROGNOSTIC MARKER IN OVARIAN-CANCER PATIENTS

被引：41
作者：
HOGDALL, CK
HOGDALL, EVS
HORDING, U
CLEMMENSEN, I
NORGAARDPEDERSEN, B
TOFTAGERLARSEN, K
机构：
[1] UNIV COPENHAGEN,RIGSHOSP,DEPT OBSTET & GYNECOL,DK-2100 COPENHAGEN,DENMARK
[2] UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN MICROBIOL,DK-2100 COPENHAGEN,DENMARK
[3] DAKO AS,GLOSTRUP,DENMARK
[4] STATENS SERUM INST,MOLEC BIOL LAB,DK-2300 COPENHAGEN,DENMARK
来源：
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION | 1993年 / 53卷 / 07期
关键词：
OVARIAN NEOPLASMS; PROGNOSIS; TETRANECTIN; TUMOR MARKER;
D O I：
10.3109/00365519309092579
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Plasma tetranectin (TN) was tested as a biochemical prognostic marker in ovarian cancer on 39 patients. In stage I + II the 5-year survival was 33% (2/6) if plasma TN was less-than-or-equal-to 6.7 mg l-1 and 100% (15/15) with plasma TN > 6.7 mg l-1. For stage III + IV the survival was 0% (0/11) at 26 months for patients with plasma TN less-than-or-equal-to 6.7 mg l-1 and 29% (2/7) after 5 years with plasma TN > 6.7 mg l-1. By multivariate testing the relative hazard (RH) of death was found to be 73 times higher in patients with plasma TN less-than-or-equal-to 6.7 mg l-1 compared to patients with values above 6.7 mg l-1 (p < 0.001). For comparison, the maximal RH for the other tested variables were: 15 for advanced stage, 2.5 for grade, four for residual tumour and 2.5 for younger age.
引用
收藏
页码：741 / 746
页数：6
相关论文
共 29 条
[1]  
AASTED B, 1971, BRIT MED J, V4, P458
[2]   A RANDOMIZED STUDY OF CYCLOPHOSPHAMIDE AND CISPLATINUM WITH OR WITHOUT DOXORUBICIN IN ADVANCED OVARIAN-CARCINOMA [J].
BERTELSEN, K ;
JAKOBSEN, A ;
ANDERSEN, JE ;
AHRONS, S ;
PEDERSEN, PH ;
KIAER, H ;
ARFFMANN, E ;
BICHEL, P ;
BOESTOFTE, E ;
CHRISTOPHERSEN, IS ;
GREGERSEN, E ;
HANSEN, MK ;
HOLUND, B ;
JACOBSEN, M ;
JENSEN, HK ;
JEPSEN, FL ;
LARSEN, G ;
NIELSEN, ES ;
NYLAND, M ;
OLSEN, J ;
PANDURO, J ;
RANK, F ;
SELL, A ;
SOGAARD, H .
GYNECOLOGIC ONCOLOGY, 1987, 28 (02) :161-169
[3]   IDENTIFICATION OF A HIGHLY MOBILIZABLE SUBSET OF HUMAN NEUTROPHIL INTRACELLULAR VESICLES THAT CONTAINS TETRANECTIN AND LATENT ALKALINE-PHOSPHATASE [J].
BORREGAARD, N ;
CHRISTENSEN, L ;
BJERRUM, OW ;
BIRGENS, HS ;
CLEMMENSEN, I .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) :408-416
[4]   OVARIAN-CANCER ANTIGEN CA125 - A PROSPECTIVE CLINICAL-ASSESSMENT OF ITS ROLE AS A TUMOR-MARKER [J].
CANNEY, PA ;
MOORE, M ;
WILKINSON, PM ;
JAMES, RD .
BRITISH JOURNAL OF CANCER, 1984, 50 (06) :765-769
[5]   IMMUNOHISTOCHEMICAL LOCALIZATION OF A NOVEL, HUMAN-PLASMA PROTEIN, TETRANECTIN, IN HUMAN ENDOCRINE TISSUES [J].
CHRISTENSEN, L ;
JOHANSEN, N ;
JENSEN, BA ;
CLEMMENSEN, I .
HISTOCHEMISTRY, 1987, 87 (03) :195-199
[6]   DIFFERENCES IN TETRANECTIN IMMUNOREACTIVITY BETWEEN BENIGN AND MALIGNANT BREAST-TISSUE [J].
CHRISTENSEN, L ;
CLEMMENSEN, I .
HISTOCHEMISTRY, 1991, 95 (05) :427-433
[7]   TETRANECTIN IMMUNOREACTIVITY IN NORMAL HUMAN-TISSUES - AN IMMUNOHISTOCHEMICAL STUDY OF EXOCRINE EPITHELIA AND MESENCHYME [J].
CHRISTENSEN, L ;
CLEMMENSEN, I .
HISTOCHEMISTRY, 1989, 92 (01) :29-35
[8]   PURIFICATION AND CHARACTERIZATION OF A NOVEL, OLIGOMERIC, PLASMINOGEN KRINGLE 4 BINDING-PROTEIN FROM HUMAN PLASMA-TETRANECTIN [J].
CLEMMENSEN, I ;
PETERSEN, LC ;
KLUFT, C .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 156 (02) :327-333
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   THE CLINICAL-SIGNIFICANCE OF PREOPERATIVE SERUM CA-125 IN OVARIAN-CANCER [J].
CRUICKSHANK, DJ ;
FULLERTON, WT ;
KLOPPER, A .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (07) :692-695
123